Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Stathmin/oncoprotein 18, a protein that regulates microtubule dynamics, is highly expressed in a number of tumors including leukemia, lymphoma, neuroblastoma, breast, ovarian, and prostate cancers. High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol ((®)Taxol, paclitaxel). The mechanisms of stathmin-mediated taxol resistance are not well-understood at the molecular level. To better understand the role of stathmin in taxol resistance, we stably overexpressed stathmin twofold in BT549 human breast cancer cells and characterized several cell processes involved in the mechanism of action of taxol. After stable overexpression of stathmin, neither the cell doubling time nor the mitotic index was altered and the microtubule polymer mass was reduced only modestly (by 18%). Unexpectedly, microtubule dynamicity was reduced by 29% after stathmin overexpression, resulting primarily from reduction in the catastrophe frequency. Sensitivity to taxol was reduced significantly (by 44%) in a clonogenic assay, and stathmin appeared to protect the cells from the spindle-damaging effects of taxol. The results suggest that in the stably stathmin-overexpressing clones, compensatory gene expression occurred that resulted in normal rates of cell proliferation and prevented the increase in catastrophe frequency expected in response to stathmin. Stathmin overexpression protected the cells from taxol-induced abnormal mitoses, and thus induced taxol resistance. Using offgel IEF/PAGE difference gel electrophoresis, we identified a number of proteins whose expression is reduced in the taxol-resistant stathmin-overexpressing cell lines, including proteins involved in the cytoskeleton and cell structure, the stress response, protein folding, glycolysis, and catalysis.
Balasubramani
Manimalha
M
Genomics and Proteomics Core Laboratories, University of Pittsburgh, Pittsburgh, PA, USA.
Nakao
Chitose
C
Uechi
Guy T
GT
Cardamone
John
J
Kamath
Kathy
K
Leslie
Kristen L
KL
Balachandran
Raghavan
R
Wilson
Leslie
L
Day
Billy W
BW
Jordan
Mary Ann
MA
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D008938:Mitosis; D008940:Mitotic Index; D009363:Neoplasm Proteins / Q000187:drug effects; D017239:Paclitaxel / Q000494:pharmacology*; D050777:Stathmin / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015854:Up-Regulation
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D050777:Stathmin; D017239:Paclitaxel
Cancer Res. 2009 Sep 1;69(17):6906-14
19671798
Proteomics. 2003 Oct;3(10):1863-73
14625848
Proteomics. 2009 Mar;9(6):1556-66
19242932
J Cancer Res Clin Oncol. 2009 Feb;135(2):181-9
18758817
Cell. 1996 Feb 23;84(4):623-31
8598048
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6
8105478
J Biol Chem. 1997 Mar 28;272(13):8129-32
9079624
Cancer Lett. 2002 Jul 8;181(1):95-107
12430184
J Cell Sci. 1999 Nov;112 ( Pt 21):3713-22
10523507
Cancer Invest. 2000;18(8):722-30
11107442
Biochemistry. 1995 Feb 21;34(7):2203-11
7857932
FEBS Lett. 2009 Jun 5;583(11):1772-84
19327356
EMBO J. 1996 Oct 1;15(19):5290-8
8895574
J Pharmacol Exp Ther. 2009 Apr;329(1):38-47
19131583
J Biol Chem. 1994 Dec 2;269(48):30626-35
7982983
Proteomics. 2007 May;7(9):1549-59
17366476
Oncogene. 2010 Jan 28;29(4):597-607
19881550
Lab Invest. 2005 Mar;85(3):316-27
15654357
Curr Cancer Drug Targets. 2007 Dec;7(8):730-42
18220533
J Proteome Res. 2009 Jul;8(7):3430-8
19485423
Cell Mol Life Sci. 2009 Oct;66(20):3263-76
19585080
J Proteome Res. 2007 Feb;6(2):772-80
17269733
Biochim Biophys Acta. 2009 Feb;1794(2):225-36
18973835
Electrophoresis. 1997 Oct;18(11):2071-7
9420172
Int J Oncol. 2007 Jun;30(6):1545-51
17487377
Proteomics. 2005 Feb;5(3):796-804
15682461
Mol Biol Cell. 2009 Aug;20(15):3451-8
19515833
Br J Cancer. 2000 Jan;82(1):142-50
10638981
Clin Chem Lab Med. 2002 Mar;40(3):221-34
12005211
J Biol Chem. 2006 Jan 27;281(4):2071-8
16317007
Mol Cell Biol. 1997 Jun;17(6):3459-67
9154845
Mol Biol Cell. 1999 Jan;10(1):105-18
9880330
J Cell Biol. 2000 May 15;149(4):767-74
10811818
Cancer Res. 2003 Sep 15;63(18):6026-31
14522931
Oncogene. 2003 Oct 20;22(47):7280-95
14576838
Proteomics. 2008 May;8(9):1744-9
18442176
Biochim Biophys Acta. 2007 Jan;1774(1):93-101
17085086
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
2359136
EMBO J. 2000 Feb 15;19(4):572-80
10675326
Cancer Res. 2002 Dec 1;62(23):6864-9
12460900
J Cell Sci. 1998 Nov;111 ( Pt 22):3333-46
9788875
J Cell Biol. 1999 Sep 20;146(6):1289-302
10491392
J Proteome Res. 2009 Apr;8(4):1902-12
19714814
Proteomics. 2009 Jan;9(1):182-93
19053080
Proteomics. 2006 Apr;6(8):2609-25
16526084